Recent news from Penn Medicine News - 18th February 2021 :-
As SYC said current CAR T treatment as amazing as it is, is only the beginning of a paradigm shift in treating cancer......
Five Years Later: Penn-developed CAR T Therapy Shows Long-lasting Remissions in Non-Hodgkin Lymphomas. Findings represent the longest follow-up data to date for a personalised cellular therapy approved by the FDA for the treatment of aggressive lymphomas
Among 24 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of NHL, who received the therapy after their cancers had come back following standard treatments, 46 percent achieved complete remission and 31 percent achieved progression-free survival at five years. Among 14 patients with relapsed or refractory follicular lymphoma, the second most common form of the disease, 71 percent achieved complete remission and 43 percent achieved progression-free survival at five years.
PTX Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
